Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.
Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.
Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.
Cancer Genetics and Epigenetics Alterations
Submission Deadline: March 15, 2019 (Open) Submit Now
Lunawati Bennett MS, PhD, PharmD, FACN Professor of Pharmaceutical Sciences, Union University College of Pharmacy, Jackson, Tennessee
About This Topic
Upcoming insight into understanding cancer genetics and epigenetic aberration of different type of cancers. Cancer is heterogeneous disease arise from defects in the structures of cells, aberration of genes, or alteration in key cellular pathways that regulate proliferation, differentiation, and apoptosis of normal cells. The mutations in cancer are usually due to gain-of-function of proto-oncogenes becomes oncogenes and/or loss function of tumor suppressor genes. Epigenetic mechanism also plays critical role in altering the patterns and levels of protein expression of certain genes, chromatin modifying protein, DNA methylation and patterns of gene expression in cancer cells. Although diverse mutations and gene expression changes have been implicated in cancer pathogenesis, the defects appear to limited number of gene alterations such as RAS, EGFR, PTEN, p53, Akt, PTEN and others; however, the accumulated multiple genetics and epigenetics defects play fundamental role in cancer initiation and progression.
Keywords: genetic defects; cancer alter signaling pathways; genomic integrity, oncogene mutations; tumor suppressor; proto oncogene; epigenetic alterations; chromatin regulator; histone hyper-methylation; histone hypo-methylation